Transcenta Closes $105 Million in Crossover Financing
12/23/20, 12:04 AM
Location
hong kong and suzhou
Money raised
$105 million
Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces today the completion of a 105 million USD crossover financing. China Structural Reform Fund led the financing round, participated by new investors including Country Garden Venture Capital, Qatar Investment Authority, and other prominent institutional investors. Existing investors including CCT China Merchants Fund, Lilly Asia Ventures, Teng Yue Partners, Sequoia Capital China and others also participated in this round. China Renaissance acted as the lead financial advisor for this transaction, and Bank of China International as joint financial advisor.
Company Info
Location
hong kong and suzhou, jiangsu, chn
Additional Info
Transcenta is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing. With Discovery and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Princeton, US and in Beijing, Shanghai and Guangzhou in China, and External Partnering Center in Boston, US, Transcenta has established global footprint. Upon the latest financing, the company has raised over $347 million from globally prominent investors. For more information, please visit www.transcenta.com.